Zobrazeno 1 - 10
of 19
pro vyhledávání: ''
Autor:
Shuji Ogino, Richard M. Goldberg, Alexander Hantel, Al B. Benson, Paul L. Schaefer, Monica M. Bertagnolli, Renaud Whittom, Leonard B. Saltz, Robert J. Mayer, Donna Hollis, Donna Niedzwiecki, Natsumi Irahara, Charles S. Fuchs, Jeffrey A. Meyerhardt
Publikováno v:
Clinical Cancer Research. 15:7322-7329
Purpose: Alterations in the RAS and RAF pathway relate to epigenetic and epigenomic aberrations, and are important in colorectal carcinogenesis. KRAS mutation in metastatic colorectal cancer predicts resistance to anti–epidermal growth factor recep
Autor:
Hsiang Lin Tsai, Hwei-Ming Wang, Jaw-Yuan Wang, Shiu-Ru Lin, Chien-Yu Lu, Yung-Sung Yeh, Yu-Tang Chang, Koung-Shing Chu, Chao-Wen Chen, Li-Chen Yen
Publikováno v:
Clinical Cancer Research. 15:4508-4513
Purpose: Previously we developed membrane-arrays as a promising tool to detect circulating tumor cells (CTC) with KRAS oncogene in patients with malignancies. This study was conducted to determinate the predictive values of CTCs with KARS mutation by
Autor:
Qiang Liu, Sanjay Goel, Carol Chandy, Radhashree Maitra, Madhukumar Venkatesh, Titto A Augustine
Publikováno v:
Cancer Research. 77:2799-2799
Introduction Development of a preclinical animal model that mimics KRAS mutated colorectal cancer disease etiology is essential for validation of new therapeutic interventions. Colorectal cancer patients with tumors harboring KRAS mutation are exclud
Autor:
Hiroshi Tazawa, Yoshiko Mori, Keisuke Kimura, Toshiyoshi Fujiwara, Kazuya Yasui, Hiroyuki Kishimoto, Toshiaki Toshima, Ajay Goel, Yuzo Umeda, Fumitaka Taniguchi, Takeshi Nagasaka, Takashi Kawai, Tomokazu Fuji
Publikováno v:
Cancer Research. 76:510-510
Introduction: Although circulating cell-free DNA (cfDNA) in blood plasma is being touted as a frontier noninvasive approaches, its clinical utility still remains questionable. The purpose of this study was to compare the efficacy of cfDNA by comparin
Autor:
Cynthia Sanchez, Scott Kopetz, Pascal Artru, Muriel Mathonnet, Denis Pezet, Olivier Bouché, Alain R. Thierry, Eric Assenat, Rosine Guimbaud, Christophe Borg, Céline Gavoille, Safia El Messaoudi, Christelle De La Fouchardiere, Jean-Luc Raoul, Marc Ychou, Caroline Mollevi, Brice Pastor
Publikováno v:
Cancer Research. 76:2632-2632
Clinical validation of circulating DNA analysis as liquid biopsy for the detection of point mutations and of the longitudinal metastatic colorectal patient follow up for detecting emergence of resistance to targeted therapy We carried out two clinica
Autor:
Evelyn Fessler, Joan H. de Jong, Gerrit K. J. Hooijer, Louis Vermeulen, Florian Markowetz, Filipe De Sousa E Melo, Xin Wang, Jan Paul Medema, Marnix Jansen, Anne Trinh
Publikováno v:
Cancer Research. 75:LB-108
BACKGROUND Recent molecular profiling of colorectal cancer has identified three distinct subtypes: two good-prognosis subtypes characterised by chromosomal instability (Subtype 1) and microsatellite instability (Subtype 2), and a poor prognosis subty
Autor:
Yoshiharu Sakai, Masayuki Ohue, Takahiro Tashiro, Masahiro Inoue, Hiroko Endo, Hiroaki Okuyama, Kenji Kawada
Publikováno v:
Cancer Research. 75:3229-3229
Purpose: Cetuximab, an anti-EGFR antibody, is clinically used in colorectal cancer (CRC) patients. Several clinical trials revealed that KRAS mutant is resistant to cetuximab. As KRAS is one of the downstream molecules in EGFR pathway, KRAS mutants a
Autor:
Mahnaz Darvish-Damavandi, Giulia Mentrast, Sarah Barton, Ian Chau, David Watkins, Sheela Rao, Khurum Khan, Naureen Starling, George Vlachogianis, David Cunningham, Nicola Valeri, Andrea Lampis, Ruwaida Begum, Francesco Trevisani, Chiara Braconi, Jens C. Hahne, Nasir Khan, Clare Peckitt, Annette Bryant
Publikováno v:
Cancer Research. 75:3589-3589
Background: AE-mABs (cetuximab and/or panitumumab) have been approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients (pts). Indeed, previous studies have identified mutations (MTs)/amplifications in RAS/RAF/MEK k
Autor:
Jill S. Barnholtz-Sloan, Sanford D. Markowitz, Peiying Yang, Joseph Willis, Stephen P. Fink, Adam Kresak, Yongyou Zhang, Levy Kopelovich, Earl Lawrence, Yanwen Chen, Dawn M. Dawson
Publikováno v:
Cancer Research. 75:2815-2815
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) protect against colorectal cancer development by inhibiting cyclooxygenase (COX) enzymes responsible for the production of tumor growth promoting prostaglandins. 15-hydroxyprostaglandin dehyd
Autor:
Zakia Amalou, Vincent Vuaroqueaux, Marielle Chiron, Rebecca G. Bagley, Heinz H. Fiebig, Anne Caron, Nina Baltes
Publikováno v:
Cancer Research. 74:4808-4808
Aflibercept (ziv-aflibercept in USA), a new fusion protein, targets vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF). Aflibercept + FOLFIRI is approved for treating metastatic colorectal cancer (mCRC) that is re